Markets:

Overview

News

Currencies

International

Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

43.70 -0.55 (-1.25%)

Streaming Delayed Price Updated: 2:28 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗

September 12, 2025

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Via Benzinga

Analyst Expectations For Dianthus Therapeutics's Future ↗

September 09, 2025

Via Benzinga

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline ↗

September 08, 2025

Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results.

Via Benzinga

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics ↗

December 20, 2024

Via Benzinga

Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts ↗

November 11, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts ↗

November 08, 2024

Via Benzinga

Top movers in Monday's pre-market session ↗

September 08, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates ↗

August 07, 2025

Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.

Via Chartmill

Dianthus (DNTH) Q2 Loss Widens 80% ↗

August 07, 2025

Via The Motley Fool

Expert Ratings For Dianthus Therapeutics ↗

September 26, 2024

Via Benzinga

Navigating 4 Analyst Ratings For Dianthus Therapeutics ↗

August 12, 2024

Via Benzinga

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics ↗

May 10, 2024

Via Benzinga

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views ↗

May 13, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers ↗

April 04, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 04, 2025

Via Benzinga

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics ↗

April 18, 2024

Via Benzinga

Decoding 4 Analyst Evaluations For Dianthus Therapeutics ↗

February 15, 2024

Via Benzinga

Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher ↗

January 22, 2024

Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement.

Via Benzinga

Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 30, 2024

Via Benzinga

DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 09, 2024

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 22, 2024

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Via Benzinga

Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗

March 22, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Via Benzinga

Topics Stocks

DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 21, 2024

DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 ↗

December 14, 2023

Dianthus Therapeutics just reported results for the third quarter of 2023.

Via InvestorPlace

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.